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Despite the presence of tumour-specific cytotoxic T cells, the
immune system fails to contain colon carcinomas (Luo et al,
1997, 2000). We now know that these malignancies engage a
variety of evasive strategies to escape immune clearance, such as
aberration of antigen processing and presentation, disruption of
T cell–extracellular matrix interactions and immunosuppression
by actively modulating and suppressing immune cell functions
(Luo et al, 1997; Halapi, 1998). As in other malignant tumours,
colon cancer cells actively suppress the immune defence of the
host by secreting a number of immunosuppressive factors (Luo
et al, 1997, 2000). However, the mechanisms by which such
factors overcome anti-tumour immunological responses are still
poorly understood. 
Recently, it has been demonstrated that a poor prognosis
of patients with colorectal carcinomas correlates with a reduced
level of tumour-infiltrating and peripheral blood lymphocytes.
This reduction may be the result of tumour immunosuppression
(Thynne et al, 1979). Fas ligand (FasL), a type II membrane-
bound 40-kDa protein which belongs to the tumour necrosis
factor (TNF) family, induces apoptotic death of sensitive
lymphoid cells expressing its cell surface receptor (FasR;
CD95/APO-I) (Nagata and Goldstein, 1995). Activated T and B
lymphocytes express FasR, and thus are sensitive to FasR-mediated
apoptosis (Krammer et al, 1994; Nagata and Goldstein, 1995).
This has been proposed to be responsible for several regulatory
functions of the immune system, including tolerance acquisi-
tion, down-regulation of immune reactions, and clonal deletion
of peripheral lymphocytes (Alderson et al, 1995; Bellgrau et al,
1995; Griffith et al, 1995; Hunt et al, 1997). FasL, which is
expressed by indigenous cells of the eye (Griffith et al, 1995)
and the testis (Bellgrau et al, 1995), mediates immune privilege
by inducing apoptosis in infiltrating pro-inflammatory mono-
nuclear cells. FasL has also been shown to confer immunological
privilege in tissue transplantation experiments. Long-term
survival was achieved in FasL-expressing allografts (Stuart
et al, 1997) and non-immune privileged cells (pancreatic islets)
co-transplanted with FasL expressing cells (Korbutt et al, 1997). 
FasL expression was also found to be expressed by various
malignant tumours, such as oesophageal (Bennett et al, 1998),
gastric (Bennett et al, 1999), colonic (O’Connell et al, 1996,
1998), which has been suggested to participate in the potential
mechanism of immune evasion in these malignancies (Strand 
et al, 1996). Membrane-bound FasL (mFasL) may be cleaved
by a specific matrix metalloproteinase-like enzyme and be
presented in a soluble form (sFasL). Human sFasL is a 26-kDa
glycoprotein consisting of an extracellular region for binding to
FasR (Tanaka et al, 1996). sFasL was constitutively secreted
by prostate cancer cells in vitro (Liu et al, 1998) and detected
in the serum of patients with malignant tumours of NK
cell origin (Tanaka et al, 1996; Kato et al, 1998). Although it is
well established that colon cancer cells express mFasL
(O’Connell et al, 1996; Krammer et al, 1998; O’Connell et al,
1998), it remains unknown whether or not they secrete sFasL.
Moreover, it remains controversial whether or not sFasL medi-
ates the same effects as mFasL- on FasR-bearing mononuclear
cells. 
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cells bore mFasL, secreted soluble FasL (sFasL) into their local
environment and thus induced apoptosis of Fas expressing
mononuclear cells without direct cell–cell contact. 
MATERIALS AND METHODS 
Patients 
A consecutive series of 12 patients who suffered from colon
adenocarcinoma diagnosed by biopsy was examined following a
protocol approved by the University Teaching Hospitals ethics
committee (5 females and 7 males; ages 47–76, mean age 62.4).
All cases underwent radical operation and none of them was found
to have metastases in distal organs. Tumours were well (n = 4),
moderately (n = 5) and poorly (n = 8) differentiated, including 2
cases of mucinous adenocarcinomas. Pathological staging was
performed according to the Dukes system, with 3 cases of Dukes
A (mucosa only), 7 cases of Dukes B (into but not through the
muscularis propria) and 2 cases of Dukes C (locally positive
nodes). Peripheral blood samples were collected one week before
and 3 weeks after operation. Sera were isolated and either freshly
used or kept in aliquots at –30˚C until used. Mononuclear cells
were isolated from the same peripheral blood samples using
Ficoll-hypaque gradient centrifugation (Accu-Prep; Accurate
Chemical, Westbury, NY, USA). Tissue samples of colon cancers
were collected after surgical resection. One part of each sample
was used for primary cell culture, the other snap-frozen in 2-
methylbutane and stored at –80˚C for further analyses. 
Measurement of sFasL level in sera 
sFasL levels in sera from 12 healthy volunteers and from all
patients 1 week before and 3 weeks after tumour resection were
measured with a sFasL enzyme-linked immunosorbent assay
(ELISA) kit (Medical and Biological Lab Co, Nagoya, Japan). The
kit detects sFasL protein by sandwich ELISA using 4H9 and 4H5
mAbs, anti-FasL monoclonal antibodies against 2 different
epitopes. In brief, 96-well plates were incubated overnight with
4H9 mAb (10 µ gm l –1). Washed with 0.05% Tween PBS (phos-
phate-buffer saline), the wells were blocked by 2% bovine
albumin (Sigma Chemical Co, St Louis, MO, USA) and PBS
overnight at 4˚C. 50 µ l of the sample, diluted twice with 1%
bovine albumin/PBS, was added to the plates and incubated for 1 h
at room temperature. Biotinylated anti-Fas monoclonal antibody,
4H5 (5 µ gm l –1), was then added and incubated for 1 h at room
temperature followed by addition of 100 µ l of steptavidin-alkaline
phosphatase (Life Technologies Gibco BRL, Grand Island, NY,
USA). After incubation for 1 h, the plates were developed with
100 µ l of 2 mg ml–1 p-nitrophenyl phosphate (Life Technologies
Gibco BRL, Grand Island, NY, USA). The optical density (OD)
was then measured at 450 nm with the use of a microplate reader.
The concentration of sFasL was calibrated from a dose–response
curve based on reference standards. 
Apoptosis assessment of peripheral mononuclear cells 
The number of apoptotic mononuclear cells isolated from periph-
eral blood was determined by terminal deoxynucleotide trans-
ferase-mediated dUTP nick end labelling (TUNEL) assay
(Boehringer Mannheim GmbH, Mannheim, Germany) and flow
cytometry. Briefly, isolated mononuclear cells were washed in
PBS, and permeabilized with 0.1% TritonX-100 in 0.1% sodium
citrate solution on ice for 5 minutes. Cells were washed again in
phosphate-buffer saline (PBS) and then incubated for 60 min at
37˚C in a labelling TUNEL-reaction mixture containing terminal
deoxynucleotidyl transferase (TdT) reaction buffer (10.0 µ l),
bromodeoxyuridine (Br-dUTP; 8.0 µ l), H2O (32.25 µ l), and TdT
(0.75 µ l). The reaction was then terminated with addition of a
rinse buffer. Cells were washed before resuspension in 0.1 ml of
PBS. Incorporated Br-dUTP was detected after the addition of
fluorescein-labelled anti-bromodeoxyuridine antibody (5.0 µ l) and
incubation for 30 min at room temperature in the dark. Flow cyto-
metric analysis was performed using a FACScan flow cytometer
with LYSIS II software (Nippon Becton Dickinson, Tokyo, Japan). 
Immunohistochemical detection of FasL protein 
Standard techniques of immunohistochemistry were used to stain
acetone-fixed 4-µ m cryostat tissue sections. Endogenous peroxi-
dase activity was quenched by incubation with 3.0% hydrogen
peroxide in methanol for 5 min. Sections were washed in PBS and
blocked for 1 h in wash buffer containing 5% normal goat serum.
A rabbit polyclonal anti-human FasL-specific immunoglobulin G
(IgG; Santa Cruz Biotechnology, Santa Cruz, CA, USA) was
added as primary antibody at 0.1 µ g ml–1 in PBS for incubation
overnight at 4˚C. After washing with PBS, the sites of primary
antibody binding were localized by sequential incubation with
biotinylated goat anti-rabbit antibody and then streptavidin conju-
gated with horseradish peroxidase (LSAB detection kit, Dako
Corp, Carpinteria, CA, USA). After further washes in PBS,
diaminobenzidine (DAB) was used as a chromogen and sections
were lightly counterstained with haematoxylin. In the control
section of each case, the peptide immunogen to which the antibody
was raised (FasL; N-terminal amino acids 260–279; Santa Cruz
Biotechnology) was included at 1 µ gm l –1 during primary antibody
incubation as a direct, internal competitive control for antibody
specificity. FasL peptide abolished staining in the tumours. 
In situ apoptosis assessment of tumour-infiltrating
lymphocytes 
To identify tumour-infiltrating lymphocytes (TILs), CD45 staining
was performed on consecutive cryosections with a mouse anti-
human CD45 monoclonal IgG (clone 2B11 +PD7/26; Dako Corp,
Carpinteria, California, USA; dilution 1/70) according to standard
immunohistochemical methods as described above. Apoptosis of
TILs was detected in situ in frozen sections of resected tissues
by terminal deoxynucleotide transferase-mediated dUTP nick
end labelling (TUNEL) assay (Boehringer Mannheim GmbH,
Mannheim, Germany) applied to the histological sections.
Visualization of the final reaction product was achieved by
diaminobenzidine (DAB). TUNEL-positive tumour-infiltrating
lymphocytes were counted at high power (× 400) from fields of
view chosen according to a systematic random sampling method.
Approximately 1000 tumour-infiltrating lymphocytes (TILs) were
counted and a TUNEL index (TI) was expressed as the percentage
of TUNEL-positive lymphocytes. 
Primary cell culture of colon cancer 
Cell suspensions derived from tumour samples were obtained by
enzymatic digestion with medium containing 0.1% collagenase
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Chemical Co, St. Louis, MO, USA). Tumour cells were isolated by
adherence to plastic culture vessels for 36 h in a 5% CO2 incubator
at 37˚C. Supernatants were discarded and tumour cells (1 ×  107)
were cultured in RPMI 1640 supplemented with 10% FCS in a
humidified 5% CO2 atmosphere. Assessment of tumour cells
was performed by light microscopy, electronic microscopy and
immunohistochemistry for keratin. 
Western blot analysis for sFasL in supernatants 
Aliquots of supernatants from cultured colon cancer cells were used
for Western blot analysis of sFasL. Proteins were isolated by
centrifugation (15 000 g for 20 min twice) and aliquots containing
20 µ g of proteins were resolved in 12% SDS-polyacrylamide gel
electrophoresis (SDS-PAGE; 12%). The separated proteins were
then transferred onto Hybond ECL filter paper (Amersham Life
Science, Arlington Heights, IL, USA), which was incubated at 25˚C
for 1 h in Blotto A (1 × PBS, 5% milk, 0.05% Tween 20) to block
unspecific binding. The filter paper was then incubated at 25˚C for 
1 h in Blotto A containing a rabbit polyclonal anti-human FasL
specific antibody in 1:200 dilution (Santa Cruz Biotechnology,
Santa Cruz, CA, USA). After washing in TBS + 0.05% Tween 20
buffer, filters were incubated for 45 min at 25˚C in TBS + 0.05%
Tween 20 buffer containing a 1:10 000 dilution of peroxidase-
conjugated secondary antibody (Amersham Life Science,
Arlington Heights, IL, USA). To visualize the result, chemilumi-
nescence reaction using the ECL system (Amersham Life
Science, Arlington Heights, IL, USA) was performed after
washing according to the procedure recommended by the manu-
facturer. 
Assessment of sFasL-induced apoptosis in Jurkat cell
line 
Jurkat human T leukaemia cells (American Type Culture
Collection, Rockville, MD, USA), which naturally express FasR
and are sensitive to Fas-mediated apoptosis, served as target cells
to evaluate the pro-apoptotic effect of sFasL containing super-
natant. Jurkat cells were cultured in DMEM (Sigma Chemical Co,
St Louis, MO, USA) supplemented with 10% fetal calf serum
(referred to hereafter as complete medium), in a humidified 10%
CO2 atmosphere. 
After washing, a total of 5 × 105 Jurkat cells were incubated for
18 h either with complete media alone or with complete media
plus cultured supernatant of colon cancer cells from each case at a
ratio of 2:1, 1:1 and 1:2, respectively. In some experiments, target
cells were pre-incubated in the presence of the antagonistic anti-
FasR blocking antibody clone ZB4 (Biovalley Co., Rockville,
MD, USA) at a final concentration of 2 µ gm l –1 for 1 h. TUNEL
assay (Boehringer Mannheim GmbH, Mannheim, Germany) and
flow cytometry were performed to quantify apoptosis of target
cells as described above. 
Statistical analysis 
All experiments for cell cultures were performed at least in tripli-
cate. Results are described as mean ± standard deviation. Statistical
analysis was performed by one-way analysis of variance (ANOVA);
comparisons between groups were performed by independent
sample  t-test or Bonferroni’s multiple-comparison t-test. To
examine the correlation between serum sFasL level and apoptosis
of peripheral blood mononuclear cells, Pearson’s correlation
coefficient was calculated. A 2-tailed P value less than 0.05 was
considered to be statistically significant. 
RESULTS 
mFasL expression in colon carcinomas and apoptosis
of tumour-infiltrating lymphocytes 
In 8 out of 12 cases (66.7%), membrane-bound FasL (mFasL) was
expressed on tumour cells of surgically resected colon cancers as
revealed by intense immunohistochemical staining, both, in the
cytoplasma and on the surface (Figure 1A). However, intensity and
extent of positive staining varied within individual tumours.
Neoplastic areas with positive and negative staining for FasL
frequently co-existed within the same tumour. Interestingly, homo-
geneous positive staining was also observed in mucin pools of
mucinous carcinomas (Figure 1B), as well as in the intracellular
mucin of signet ring cells (Figure 1C). FasL expression also
existed on tumour-infiltrating lymphocytes (TILs) in all cases, and
the staining was weaker than in positive tumour regions.
Additionally, FasL-positive TIL counts were independent of FasL
expression on colon cancer cells (data not shown). Fas ligand
specificity was confirmed in consecutive control sections with the
Fas ligand peptide immunogen as an internal competitive control.
Co-incubation with immunogen resulted in direct, competitive
displacement of positive staining (not shown) whereas co-incuba-
tion with an irrelevant peptide had no effect. No immunostaining
was observed in normal mucosal or glandular epithelial cells at the
border of the tumours. The extent of mFasL expression did not
vary between different cancer stagings or differentiations. 
Leukocyte infiltration in tumours was demonstrated in all 12
carcinomas by CD45 immunohistochemical staining. Most of the
CD45-positive cells were of lymphoid morphology (not shown).
To evaluate apoptosis of tumour-infiltrating lymphocytes, we
studied the presence of apoptotic cells in tissue sections by
staining of DNA fragments with the TUNEL technique. TUNEL-
stained nuclei were primarily found among the infiltrating
lymphoctes, both adjacent (Figure 1D) and distal to tumour nests
(Figure 1E). Apoptotic cells were detected even among lympho-
cytes surrounding normal glands close to tumour nests, but
without direct physical contact to tumour cells (Figure 1F). 
To quantify the extent of apoptosis in lymphocytic infiltrates,
the percentage of TUNEL-positive cells was calculated. In mFasL
positive colon cancers 2.1 ± 0.9% of infiltrating lymphocytes were
TUNEL-positive, as compared to 0.73 ± 0.34% in mFasL-negative
cancers (P = 0.016) (Figure 2). 
Serum FasL and apoptosis of peripheral blood
lymphocytes 
Using ELISA, the level of soluble FasL (sFasL) was determined in
the serum of colon cancer patients before and after tumour resection.
Elevated sFasL levels were only detected in mFasL-positive individ-
uals before tumour resection (Figure 3). One week before tumour
resection, sFasL levels of membrane bound FasL-positive individ-
uals (n = 8) ranged from 280 to 750 pg mL–1 (480 ± 163; 3 patients
had sFasL levels exceeding 500 pg ml–1). However, 3 weeks after
tumour resection sFasL levels were undetectable (< 50 pg ml–1) in all
patients. sFasL was also undetectable in sera from healthy volunteers
Soluble Fas ligand in colon cancer 1049
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sion in tumour tissues before or after tumour resection. 
There was a significant relationship between sFasL in serum
and the number of peripheral blood mononuclear cells (PBMC)
undergoing apoptosis (Figure 4) as determined by the TUNEL
assay and flow cytometry. In those patients whose sFasL levels
were elevated (n = 8), the percentage of apoptotic PBMCs before
tumour resection was 0.70 ± 0.20%, and dropped to 0.32 ± 0.11%
3 weeks after tumour resection, at which time sFasL levels were
undetectable (P < 0.01). Thus, it was not surprising that the
number of apoptotic PBMCs was equally low in cases with unde-
tectable sFasL (0.34 ± 0.17% before and 0.29 ± 0.13% after
tumour resection). To further demonstrate the relationship between
sFasL levels and the number of apoptotic PBMCs, we conducted a
bivariate correlation analysis and calculated the Pearson’s correla-
tion coefficient for the 8 cases with detectable serum sFasL. The
apoptotic index of PBMCs was positively correlated to serum
sFasL levels (r = 0.942, P < 0.01) (Figure 5). 
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Figure 1 Fas ligand expression in colon adenocarcinomas (A, B and C) and TUNEL staining of tumour-infiltrating lymphocytes (D, E and F). FasL-positive
immunohistochemical staining (brown, × 400) is shown in a representative colon carcinoma (A), in the mucin pool of a mucinous carcinoma (B), and in the
intracellular mucin of signet ring cells (arrowhead) of a mucinous carcinoma (C). TUNEL-positive staining (arrowhead) was detected in the infiltrating
lymphocytes surrounding tumour nests (D, × 400), in the lymphocytes distal to the tumour nest (E, × 200), and in those surrounding normal colon glands at the
resection rim (F, × 400) 
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Colon cancer cells release sFasL 
To further determine whether colon cancer cells can release sFasL
into their local environment, tumour cells were isolated from each
resected sample and primarily cultured. Purity of cancer cells, as
assessed by light microscopy, electronic microscopy and immuno-
histochemistry for keratin, was more than 97% in each case (not
shown). After 48 h, supernatants were collected and assayed for
sFasL. Upon immunoblotting with anti-FasL antibodies, a band
migration with an apparent molecular mass of 26 kDa that corre-
sponded to sFasL and represented the cleaved fragment from the
40 kDa mFasL was observed in the 8 cases with positive mFasL
expression in tumour tissues and detectable sFasL levels in sera
(Figure 6). sFasL was not observed in the supernatants of the other
4 cases without mFasL expression in tumour tissues, as well as in
fresh media alone. Besides, in none of the samples could the
40 kDa mFasL be detected in the supernatant. 
sFasL containing supernatants induce apoptosis in
Jurkat cells 
To test whether sFasL, released by colon cancer cells, can cause 
Fas-dependent apoptosis of target cells, we incubated Fas-expressing
Jurkat cells in media supplemented with supernatants from
primarily cultured colon cancer cells at different dilutions.
Complete media without supernatant was used as negative control.
After 18 h of incubation, the percentage of apoptotic Jurkat cells
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than in the ones exposed to complete media or to supernatants
without sFasL (P < 0.05) (Figure 7). The percentage of cell death
increased with the ratio of sFasL containing supernatant to media
(P < 0.05), being elevated to 28.7 ± 3.5% at a ratio of 1:2 and 57.1 ±
4.3% at a ratio of 2:1. Supernatants without sFasL did not influence
the number of apoptotic cells in comparison to complete media.
To determine whether apoptosis of Jurkat cells, exposed to
sFasL-containing supernatants, was indeed Fas-mediated, we pre-
treated target cells with 2 µ gm l –1 of antagonistic anti-FasR-
blocking antibody clone ZB4. ZB4 treatment specifically reduced
the apoptotic percentage of Jurkat cells exposed to sFasL-
containing supernatants at the highest supernatant to media ratio
(2:1) (4.8 ± 1.3% vs. 59.7 ± 5.2% in non-treated cells; P < 0.01).
ZB4 monoclonal antibody alone did not influence the apoptosis of
Jurkat cells (data not shown). 
DISCUSSION 
Colon cancer cells have been reported to express membrane-
bound FasL (mFasL) on their surfaces and thus conduct immune
evasion by inducing apoptosis in Fas-expressing lymphocytes
(O’Connell et al, 1996, 1998). The requirement of a cell–cell
contact was suggested in this type of cell killing (Oyaizu et al,
1997). Recently, the functional soluble form of FasL (sFasL),
which consists of the extracellular region of FasL, was identified
(Tanaka et al, 1996). The main goal of this study was to determine
whether colon cancer cells can release sFasL into host circulation,
and whether such soluble extracellular fragment of mFasL may
induce apoptotic cell death in host lymphocytes. 
We found that high sFasL levels were present in the serum of
patients with mFasL-positive colon cancers before tumour resec-
tion. High levels of sFasL in serum have been detected in several
haematological diseases, including NK-cell leukaemia, NK-cell
lymphoma, haemophagocytic lymphohistocytosis, leukaemia of T-
cell-type large granular lymphocytes and B-cell non-Hodgkin’s
lymphoma (Sato et al, 1996; Tanaka et al, 1996; Kato et al, 1998;
Murayama et al, 1999; Saito et al, 1999). In these cases, sFasL
levels dropped in parallel to the reduced burden of malignant cells
following radiotherapy or chemotherapy (Sato et al, 1996; Kato et
al, 1998). However, up to now, evidence for the potential of non-
lymphoid tumours to release the soluble form of FasL is rare (Liu
et al, 1998). 
In the present study, the elevated levels of sFasL were reduced 
to undetectable levels after surgical resection of colon tumours
expressing membrane-bound FasL. Furthermore, as we could not
detect sFasL in colon cancers negative for membrane bound FasL,
sFasL is likely to be released by mFasL-positive colon cancer cells. 
More interestingly, in the 2 cases of mucinous adenocarci-
nomas, which expressed mFasL on the cell surface, we found
strong homogenous FasL-specific immunostaining in the extracel-
lular and intracellular mucin secreted or to be secreted by these
tumour cells. Since sFasL consists of the extracellular region of
mFasL for binding to Fas, it can be detected by immunostaining
with anti-FasL immunoglobulin (Liu et al, 1998). Hence, the
FasL-specific immunostaining in mucin further supports that
colon cancer cells release sFasL. However, it has been demon-
strated that sFasL is secreted by activated lymphocytes in
inflammation (Toyozaki et al, 1998; Takeda et al, 1999) and graft-
versus-host disease (Das et al, 1999). As lymphocytes are present
in areas of carcinomas, they might be responsible for the elevated
sFasL levels in the sera of colon cancer patients. To testify that
colon cancer cells released sFasL, we studied the supernatants of
primary cultures for the tumour cells. We could demonstrate that
sFasL was present in supernatants of primarily cultured cancer
cells from individuals whose serum sFasL levels were markedly
elevated, but not in those with undetectable serum sFasL. This
confirms that colon cancer cells, rather than TILs, are the major
potential source of sFasL. 
Lymphocytes in peripheral blood or infiltrating tumour tissues
play an important role in anti-tumour immunity. Decrease in
tumour-infiltrating and peripheral blood lymphocytes is a charac-
teristic feature of immune evasion in colon cancer (Thynne et al,
1979; Halapi, 1998). The mechanism of lymphocytic apoptosis is
not fully understood. Studies on other malignancies have shown a
parallel increase in the number of apoptotic tumour-infiltrating
lymphocytes (TILs) and mFasL expression on cancer cells,
suggesting that tumour cells may kill TILs by a Fas-dependent
mechanism (Bennett et al, 1998; Younes et al, 2000). Our data
supported this by showing that apoptosis prevailed in TILs of
mFasL-positive colon cancers. Furthermore, we found that in
addition to a large number of TUNEL-positive lymphocytes
surrounding the tumour, lymphocytes that were distal to tumour
nests or even adjacent to normal glands near the tumour exhibited
a higher percentage of apoptosis than those in mFasL-negative
cancers. Since activated T, B and NK cells, neutrophils, and mono-
cytes are sensitive to apoptosis induced by sFasL (Matsumoto
et al, 2000; Sporer et al, 2000), the increase in apoptosis of
lymphocytes distal to tumour nests, herein, may result from sFasL
released by FasL-positive tumour cells. 
Accordingly, we also found that the percentage of apoptotic
peripheral blood mononuclear cells (PBMCs) was closely correlated
with serum sFasL levels. A sharp plunge in the number of apoptotic
PBMCs after tumour resection was observed in mFasL-positive
colon cancers. This suggests that serum sFasL released by colon
cancer cells is biologically active, and induces apoptosis in PBMCs,
which may contribute to the immune evasion of colon cancers. 
It has been demonstrated by other groups that elevated soluble
FasL in serum may cause tissue damages in heart, liver and kidney
(Sotozono et al, 1998; Toyozaki et al, 1998; Das et al, 1999;
Matute-Bello et al, 1999; Mukai et al, 2000; Sotozono et al, 2000).
sFasL present in the bronchoalveolar lavage fluid of patients with
ARDS (Matute-Bello et al, 1999) induces apoptosis of cells of the
distal pulmonary epithelium during acute lung injury. In our study,
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slight increase in serum bilirubin levels (higher than 17 µ mol l–1)
in 2 cases with detectable sFasL. The discrepancy between our
results and the results of others may be explained by the fact that
target cells in damaged organs reported by other groups were acti-
vated to express large amount of Fas by concomitant pathogens
(Toyozaki et al, 1998). 
The role of sFasL in apoptosis induction has been controversial.
In-vitro sFasL exerted an anti-apoptotic effect by competing with
membrane-bound FasL for its binding to Fas (Oyaizu et al, 1997).
Tanaka et al found that release of sFasL down-regulated the
expression of mFasL (Tanaka et al, 1998). However, sFasL was
also found to exert lethal effects on Fas-bearing cells both in vitro
and in vivo (Shiota et al, 1998; Toyozaki et al, 1998; Ghio et al,
1999). In acute self-limited and fulminant hepatitis, serum sFasL
levels paralleled the severity of liver damage (Shiota et al, 1998).
Besides, serum sFasL in allogeneic blood for transfusion exerts
immunosuppression to recipients by inducing apoptosis of Fas-
positive lymphocytes (Ghio et al, 1999). 
In order to clarify whether apoptosis of peripheral blood and
tumour-infiltrating lymphocytes was mediated by sFasL released
by colon cancer cells, we evaluated the biological activity of sFasL
in the supernatants of primarily cultured colon cancer cells.
Massive apoptosis was achieved in Fas-sensitive Jurkat cells
treated with sFasL-containing supernatants in a dose-dependent
manner, but not in those without sFasL. These effects were abol-
ished when antagonistic anti-FasR blocking antibody was applied.
Thus, the apoptosis of Jurkat cells in our study was Fas-mediated. 
Our findings suggest that sFasL is biologically active and
mediates apoptosis of Fas-bearing lymphocytes. Two possible
hypotheses may explain the distinct findings regarding the biolog-
ical effect of soluble FasL. Gustavo et al proposed that a cofactor
may be required for an apoptotic response to sFasL, as higher
concentrations of sFasL were required to induce apoptosis in vitro,
while a much lower amount was needed in the bronchoalveolar
lavage containing cofactors in ARDS subjects (Matute-Bello et al,
1999). This is supported by the observation that colon cancer cells
can secrete various kinds of immunosuppressive factors (Luo et al,
1997), which may serve as co-factors for sFasL. Pascal et al
suggested that limited mutations in amino acid residues of sFasL
result in distinct differences of its biological activity (Schneider
et al, 1997). Hence, minor differences in the amino acid sequence
of sFasL in cancer cells from other cell types might also explain
the different pro-apoptotic effects in different studies. 
Overall, our present findings suggest that soluble FasL is
released by FasL-positive colon cancer cells, and actively
suppresses host immunity by inducing apoptosis of peripheral
blood lymphocytes, as well as tumour-infiltrating lymphocytes.
Although our previous study has shown that colon cancer cells
may be sensitized to FasR-mediated apoptosis upon exposure to
cirrhotic Kupffer cells (Song et al, 2001), under normal circum-
stances, they lack FasR expression, and thus may avoid suicide
induced by their own soluble Fas ligand. 
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